BUSINESS SEGMENT INFORMATION The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's chief operating decision maker ("CODM"), assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers, including patients, clinicians, hospitals, IDNs, health plans, employers and ACOs. The Company is the world's leading provider of diagnostic information services, which includes providing information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. The DIS business accounted for approximately 95% of net revenues in 2018 , 2017 and 2016 . All other operating segments include the Company's DS businesses, which consists of its risk assessment services, healthcare information technology, and diagnostic products (prior to disposition on May 13, 2016) businesses. The Company's DS businesses are the leading provider of risk assessment services for the life insurance industry and offer healthcare organizations and clinicians robust information technology solutions. In addition to the sale of Focus Diagnostics (see Note 7) in 2016, the Company wound down its Celera products business, which did not have a material impact on the Company's consolidated financial statements. As a result of these transactions, the Company has disposed of its diagnostics products business. As of December 31, 2018 , substantially all of the Companys services were provided within the United States, and substantially all of the Companys assets were located within the United States. The following table is a summary of segment information for the years ended December 31, 2018 , 2017 and 2016 . Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets, other operating income and expenses net of certain general corporate activity costs that are allocated to the DIS and DS businesses, and the gain on disposition of businesses associated with the dispositions of Focus Diagnostics (see Note 7). The accounting policies of the segments are the same as those of the Company as set forth in Note 2. 2018 2017 2016 Net revenues: DIS business $ 7,204 $ 7,068 $ 6,837 All other operating segments 327 334 377 Total net revenues $ 7,531 $ 7,402 $ 7,214 Operating earnings (loss): DIS business $ 1,235 $ 1,313 $ 1,244 All other operating segments 47 52 64 General corporate activities (181 ) (200 ) (31 ) Total operating income 1,101 1,165 1,277 Non-operating expenses, net (175 ) (135 ) (191 ) Income before income taxes and equity in earnings of equity method investees 926 1,030 1,086 Income tax expense (182 ) (241 ) (429 ) Equity in earnings of equity method investees, net of taxes 44 35 39 Net income 788 824 696 Less: Net income attributable to noncontrolling interests 52 52 51 Net income attributable to Quest Diagnostics $ 736 $ 772 $ 645 Depreciation and amortization expense for the years ended December 31, 2018 , 2017 and 2016 were as follows: 2018 2017 2016 DIS business $ 213 $ 189 $ 170 All other operating segments 6 6 6 General corporate 90 75 73 Total depreciation and amortization $ 309 $ 270 $ 249 Capital expenditures for the years ended December 31, 2018 , 2017 and 2016 were as follows: 2018 2017 2016 DIS business $ 330 $ 219 $ 264 All other operating segments 16 15 21 General corporate 37 18 8 Total capital expenditures $ 383 $ 252 $ 293 Net revenues by major service for the years ended December 31, 2018 , 2017 and 2016 were as follows: 2018 2017 2016 Routine clinical testing services $ 4,217 $ 4,006 $ 3,878 Gene-based and esoteric (including advanced diagnostics) testing services 2,409 2,449 2,335 Anatomic pathology testing services 578 612 624 All other 327 335 377 Total net revenues $ 7,531 $ 7,402 $ 7,214